Hemodynamic Parameters Changes in the Course of Hemodialysis Sessions in Patients With Intradialytic Hypertension

June 10, 2019 updated by: Khaled Khazim, MD, Western Galilee Hospital-Nahariya

While the exact pathogenesis of Intradialytic hypertension remains to be determined, several mechanisms were proposed to be involved. The main factors to determine the arterial blood pressure are the peripheral vascular resistance and cardiac output. The assumption is that the increase of blood pressure is related to the increase in peripheral vascular resistance during the dialysis session, due to fluid removal and fast reduction of the intravascular volume reduction.

Using the NICAS device (Non-Invasive Cardiac System), the hemodynamic profile in patients with intradialytic hypertension will be evaluated

Study Overview

Status

Completed

Detailed Description

The number of patients with end stage renal disease (ESRD) is growing worldwide and nowadays hemodialysis (HD) treatment is the prevalent modality of renal replacement therapy. Paradoxically an increase of BP during or immediately after the HD sessions has been observed in some patients. This phenomenon is referred to as Intradialytic Hypertension (IDH). The focus will be on systolic BP increase ≥ 10 mmHg during or immediately after hemodialysis which results in post-dialysis hypertension BP above ≥130/80 mmHg. IDH affects up to 10-15% of hemodialysis patients. Patients with IDH have unfavorable outcomes; previous epidemiological data showed that IDH is associated with higher cardiovascular morbidity and mortality rates.

From the view of hemodynamic profile, peripheral resistance and cardiac output are the most important factors contributing to arterial blood pressure. The pathogenesis of IDH is likely to be multifactorial. Several mechanisms were proposed to be involved in the pathogenesis of this phenomenon.

Endothelial dysfunction, increased activity of the renin angiotensin aldosterone system (RAAS) and activation of the sympathetic nervous system had been shown to be involved in the increase of blood pressure during Hemodialysis in this group of patients.

None of these possible explanations or their inter-relationships has been studied in a controlled experimental setting and the actual physiological changes during hemodialysis in intradialytic hypertensive patients still remain unexplored.

The NICAS (Non-Invasive Cardiac System) device, used mainly for noninvasive cardiac diagnostic purposes, is substantially equivalent to the use of other hemodynamic evaluation tools, yet it is non-invasive and provides on-line data regarding the hemodynamic status of patients. Using this device, the hemodynamic changes during the HD session of IDH patients will be investigated.

By using the NICAS device, the hemodynamics parameters changes during the dialysis session will be measured. The parameters that will be measured are heart rate, stroke volume, cardiac index, cardiac power index and total peripheral vascular resistance.

During the hemodialysis treatment several hemodynamic changes may occur due to intravascular volume reduction. Changes in peripheral vascular resistance, cardiac output and cardiac power index contribute to the hemodynamic stability during the dialysis session.

By using a non-invasive technique, the NICAS device,hemodynamic changes that occur during the hemodialysis session will be evaluated.

An increase of blood pressure is correlated with the increase of peripheral vascular resistance and/or the increase of cardiac output, reflecting an adjustment to the fast changes in the intravascular volume.

Aim of the study The hemodynamic changes that occur during the dialysis session in patients with intradialytic hypertension by using the NICAS device will be evaluated.

Methods This will be an observational prospective study that examines hemodynamic parameters before and immediately after the dialysis session.

The hemodynamic data is collected by the investigators during the study period. These parameters will be obtained before starting the dialysis session, every hour during the dialysis session and at the end of it.

Study Type

Observational

Enrollment (Actual)

22

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Nahariya, Israel
        • Western Galilee Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Twenty two patients on Chronic Hemodialysis treatment that exhibit intradialytic hypertension in the dialysis unit in the Galilee Medical Center will be included during 2016-2017.

Description

Inclusion Criteria:

  • Intradialytic hypertension at least once weakly
  • Age older than 18 years
  • Chronic hemodialysis treatment more than 3 months
  • Stable dialysis treatment conditions
  • Stable antihypertensive treatment for the last 4 weeks prior the study
  • Patients able and agree to sign the consent form.

Exclusion Criteria:

  • Recent changes in the antihypertensive treatment
  • Recent acute cardiovascular event

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peripheral vascular resistance (dyne/sec/cm5)
Time Frame: During 3 consecutive hemodialysis session in one week
In patients with intradialytic hypertension
During 3 consecutive hemodialysis session in one week
Stroke volume (ml)
Time Frame: During 3 consecutive hemodialysis session in one week
In patients with intradialytic hypertension
During 3 consecutive hemodialysis session in one week
Stroke index (ml/m2)
Time Frame: During 3 consecutive hemodialysis session in one week
In patients with intradialytic hypertension
During 3 consecutive hemodialysis session in one week
Cardiac output (l/min)
Time Frame: During 3 consecutive hemodialysis session in one week
In patients with intradialytic hypertension
During 3 consecutive hemodialysis session in one week
Cardiac index (l/min/m2)
Time Frame: During 3 consecutive hemodialysis session in one week
In patients with intradialytic hypertension
During 3 consecutive hemodialysis session in one week
Heart rate (bpm)
Time Frame: During 3 consecutive hemodialysis session in one week
In patients with intradialytic hypertension
During 3 consecutive hemodialysis session in one week
blood pressure (mm/Hg)
Time Frame: During 3 consecutive hemodialysis session in one week
In patients with intradialytic hypertension
During 3 consecutive hemodialysis session in one week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 1, 2016

Primary Completion (ACTUAL)

December 1, 2017

Study Completion (ACTUAL)

December 1, 2017

Study Registration Dates

First Submitted

January 25, 2017

First Submitted That Met QC Criteria

January 29, 2017

First Posted (ESTIMATE)

January 31, 2017

Study Record Updates

Last Update Posted (ACTUAL)

June 11, 2019

Last Update Submitted That Met QC Criteria

June 10, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GMC170114CTIL

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intradialytic Hypertension

Subscribe